A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
Immune checkpoint inhibitor (ICI) have demonstrated efficacy in treating various cancers by modulating the immune system, but this can lead to immune-related adverse events (irAEs), including myocarditis. ICI-associated myocarditis is a rare but highly lethal irAE with a short mean time to onset, an...
Saved in:
| Main Authors: | Le Xu, Yukai Chen, Lin Xiong, Yang Shen, Zhuolin Zhou, Siyu Wang, Ximing Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2512645 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment
by: John Storwick, et al.
Published: (2025-07-01) -
Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)
by: Clémence M. C. Huigen, et al.
Published: (2025-08-01) -
Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events
by: Khashayar Esfahani, et al.
Published: (2025-02-01) -
Immune checkpoint inhibitor myocarditis: a systematic case study
by: E. A. Kushnareva, et al.
Published: (2020-12-01) -
Peripheral blood markers predict prognosis and irAEs of stage IV driver gene-negative lung adenocarcinoma treated with ICIs
by: Yu Li, et al.
Published: (2025-03-01)